Viking Therapeutics Shares Face Mounting Pressure Amid Clinical and Financial Setbacks

Financial Strain Intensifies

Viking Therapeutics finds itself navigating turbulent waters as its stock experiences a pronounced downward trajectory. Investor confidence has been significantly undermined by disappointing trial outcomes for a key drug candidate and a rapidly deteriorating financial position, firmly establishing the stock within a bearish trend.

The company’s financial health shows alarming signs of distress, compounding existing challenges. Recent figures reveal a substantial widening of losses, with the GAAP net loss for Q2 2025 reaching $65.6 million. This represents a dramatic increase compared to the $22.3 million loss reported during the same quarter last year. Market experts have responded by significantly revising their loss-per-share estimates upward for the 2025 fiscal year over the past two months.